


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A compound of Formula I



wherein:

R¹ is C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>OCH<sub>2</sub>-, C<sub>6</sub>H<sub>5</sub>(CH<sub>2</sub>)<sub>3</sub>- or indol-3-ylmethyl;

Y is ~~pyrrolidinyl~~ pyrrolidinyl, 4-methyl-piperidinyl or NR<sup>2</sup>R<sup>2</sup>;

R<sup>2</sup> are each independently a ~~C<sub>1</sub>-to-C<sub>6</sub>-alkyl~~ C<sub>1</sub>-C<sub>6</sub> alkyl;

R³ is ~~2-naphthyl~~ or phenyl para-substituted by W;

W is H, F, CF<sub>3</sub>, ~~C<sub>1</sub>-C<sub>6</sub>-alkoxy~~ or ~~phenyl~~;

R⁴ is ~~H~~ or CH<sub>3</sub>;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (canceled).

Claim 3 (currently amended): A compound of Claim 1 wherein said compound has the (R,R) stereoconfiguration.

Claim 4 (original): A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.

Claim 5 (original): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 6 (original): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 7 (original): A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.

Claim 8 (currently amended): A method according to Claim 7 5 which further comprises administering to a patient a bone-antiresorptive agent.

Claim 9 (original): A method according to Claim 8 wherein said bone-antiresorptive agent is a bisphosphonate.

Claim 10 (new): A compound of Claim 1 wherein  $R^1$  is  $C_6H_5(CH_2)_3-$  and Y is pyrrolidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 11 (new): A compound of Claim 1 wherein  $R^1$  is  $C_6H_5CH_2OCH_2-$  and Y is pyrrolidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 12 (new): A compound of Claim 1 wherein  $R^1$  is  $C_6H_5(CH_2)_3-$  and Y is 4-methylpiperidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 13 (new): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 10, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 14 (new): A pharmaceutical formulation according to Claim 13 which further comprises a bone-antiresorptive agent.

Claim 15 (new): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth

Serial No. 09/890,163

hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 10 or a pharmaceutically acceptable salt or solvate thereof.